Patents by Inventor Matthew C. Rhodes

Matthew C. Rhodes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11919910
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: March 5, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Xuechao Xing, Yong He, Matthew C. Rhodes, Yat Sun Or
  • Publication number: 20230331734
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit picornavirus, norovirus or coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 4, 2023
    Publication date: October 19, 2023
    Inventors: Hui Cao, Jiajun Zhang, Xuechao Xing, Matthew C. Rhodes, Xuri Gao, Wei Li, Yat Sun Or
  • Publication number: 20230203048
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 9, 2022
    Publication date: June 29, 2023
    Inventors: Guoqiang Wang, Ruichao Shen, Xuechao Xing, Yong He, Matthew C. Rhodes, Yat Sun Or
  • Publication number: 20230122228
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 14, 2022
    Publication date: April 20, 2023
    Inventors: Ruichao Shen, Yong He, Xuechao Xing, Matthew C. Rhodes, Joseph D. Panarese, Samuel Bartlett, Wei Li, Hui Cao, Jiajun Zhang, Xiaowen Peng, Guoqiang Wang, Yat Sun Or
  • Patent number: 11325916
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: May 10, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Ruichao Shen, Yong He, Xuechao Xing, Matthew C. Rhodes, Guoqiang Wang, Yat Sun Or